EDINA, Minn., March 15, 2023 (Newswire.com) - TTC Oncology ("TTC" or the "Company") announced the signing of a Collaboration Agreement (the "Agreement") with Lantern Pharma Inc. ("LTRN") to expand the clinical development of the TTC drug candidate TTC-352. The Phase-2 ready candidate, TTC-352, is an orally available small molecule being developed as a treatment for patients with metastatic estrogen receptor-positive ("ER+") breast cancer who have failed two or more prior therapies. TTC-352 is a first-in-class selective human ER partial agonist (ShERPA) that in metastatic disease causes ER to induce breast cancer cell death.
The collaboration will be powered by Lantern's artificial intelligence (AI) platform, RADR®, and its 25+ billion oncology-focused data points, 200+ advanced ML algorithms, as well as its four multi-faceted AI drug discovery and development modules. The initial aims of the collaboration will be to 1) identify biomarker or gene signatures to power potential patient selection for an upcoming TTC-352 Phase 2 clinical trial, 2) further characterize TTC-352's mechanism of action, and 3) discover additional treatment indications for TTC-352.
Breast cancer afflicts approximately 2.1 million women in the U.S. yearly with the majority of these cases being ER+, in which ER promotes tumor growth. Patients with ER+ breast cancer are initially treated with endocrine therapy, which blocks the tumorigenic actions of ER. Unfortunately, almost half of all patients who undergo endocrine therapy develop endocrine-resistant metastatic disease and will need chemotherapy as a last resort. TTC-352 provides an alternative approach without the toxicity associated with chemotherapy.
Under the terms of the collaboration, Lantern Pharma is receiving an exclusive right to license TTC-352, including any collaboration intellectual property (IP), during an exclusive option period. Additionally, Lantern and TTC will each participate in upfront, milestone, and royalty payments in the event a third party licenses IP resulting from the collaboration. No further financial details were disclosed.
About Lantern Pharma
Lantern Pharma ("LTRN") is a clinical-stage oncology-focused biopharmaceutical company leveraging its proprietary RADR® AI and machine learning platform to discover biomarker signatures that identify patients most likely to respond to its pipeline of genomically-targeted therapeutics. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, Lantern's approach represents the potential to deliver best-in-class outcomes. For more information, please visit the company's website at www.lanternpharma.com.
About TTC Oncology LLC
TTC Oncology is an emerging biotechnology company founded in 2015. TTC Oncology's mission is to develop and bring to market a novel, small-molecule therapy, TTC-352, to address the unmet needs of breast cancer patients. TTC has a license from the University of Illinois at Chicago covering the therapy. https://ttconcology.com/ TTC is currently raising funds to complete Phase II studies.
Contact Information:Joe Cunningham
CFO
joe@worldview.capital
6129911778
Original Source: TTC Oncology LLC Signs a Collaboration Agreement With Lantern Pharma
